A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing.
Fracasso PM, Burris H 3rd, Arquette MA, Govindan R, Gao F, Wright LP, Goodner SA, Greco FA, Jones SF, Willcut N, Chodkiewicz C, Pathak A, Springett GM, Simon GR, Sullivan DM, Marcelpoil R, Mayfield SD, Mauro D, Garrett CR.
Fracasso PM, et al. Among authors: sullivan dm.
Clin Cancer Res. 2007 Feb 1;13(3):986-93. doi: 10.1158/1078-0432.CCR-06-1542.
Clin Cancer Res. 2007.
PMID: 17289894
Clinical Trial.